In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving Kedrion Corporate site. Medical information including licensed uses may be different outside of the EU countries.
NO
YES
Key figures
Kedrion is a leading biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders.
With a commercial presence in 100 countries, we operate through a fully integrated business model from the collection of plasma in our own centers in the United States, Hungary and Germany to fractionation and production in our manufacturing facilities located in Italy, Hungary and the United States.
PRESS RELEASES
Updated Bylaws
Kedrion’s Extraordinary Meeting of Shareholders approves the amendment of the Company’s Bylaws
read moreShareholders’ Agreement
Sestant Internazionale, Sestant and FSI Investimenti sign a new Shareholders’ Agreement concerning Kedrion
read more
KEDRION NOTES
For more information please contact: investor@kedrion.com
Where 